Subgroup
| |
n
|
Mortality (n [%])
|
OS (P)
|
---|
Chemotherapy (n = 61)
|
c-myc
|
Amplified
|
19
|
1 (5.3)
|
0.7442
|
|
Nonamplified
|
42
|
3 (7.1)
| |
HER-2/neu
|
Amplified
|
26
|
0 (0.0)
|
0.1042
|
|
Nonamplified
|
35
|
4 (11.4)
| |
Endocrine therapy (n= 99)
|
c-myc
|
Amplified
|
15
|
1 (6.7)
|
0.9846
|
|
Nonamplified
|
84
|
6 (7.1)
| |
HER-2/neu
|
Amplified
|
22
|
2 (9.1)
|
0.8307
|
|
Nonamplified
|
77
|
5 (6.5)
| |
No therapy (n = 21)
|
c-myc
|
Amplified
|
5
|
2 (40.0)
|
0.0098*
|
|
Nonamplified
|
16
|
1 (6.3)
| |
HER-2/neu
|
Amplified
|
7
|
1 (14.3)
|
0.5649
|
|
Nonamplified
|
14
|
2 (14.3)
| |
- *P < 0.05 (log-rank test). OS, overall survival.